Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
Andrea Duminuco, Antonella Nardo, Gaetano Giuffrida, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2188-2188
Open Access | Times Cited: 16

Showing 16 citing articles:

Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis
Mariarita Spampinato, Cesarina Giallongo, Sebastiano Giallongo, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Debulking Therapy with Obinutuzumab Is Helpful and Safe in Chronic Lymphocytic Leukemia with Extreme Hyperleukocytosis: A Case Report
Dario Leotta, Andrea Duminuco, Marina Parisi, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 10-10
Open Access
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
Andrea Duminuco, Elena Torre, Giuseppe A. Palumbo, et al.
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 5, pp. 176-189
Closed Access | Times Cited: 14
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Emergencies in Hematology: Why, When and How I Treat?
Andrea Duminuco, Vittorio Del Fabro, Luca Patanè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7572-7572
Open Access | Times Cited: 3
Polycythemia Vera: Barriers to and Strategies for Optimal Management
Andrea Duminuco, Patrick Harrington, Claire Harrison, et al.
Blood and Lymphatic Cancer Targets and Therapy (2023) Vol. Volume 13, pp. 77-90
Open Access | Times Cited: 8
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 13, pp. 1449-1461
Closed Access | Times Cited: 7
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Abdulraheem Yacoub, Nicole Twardowski, Alec Britt, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 8, pp. 506-511
Open Access | Times Cited: 2
Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review
Jiahao Song, Chanzi Huang, Lina Jia, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease
Lucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4273-4273
Open Access | Times Cited: 1
AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
Andrea Duminuco, Adrián Mosquera Orgueira, Antonella Nardo, et al.
Cancer Reports (2023) Vol. 6, Iss. 10
Open Access | Times Cited: 4
Myelofibrosis: In Search for BETter Targeted Therapies
Giuseppe A. Palumbo, Andrea Duminuco
Journal of Clinical Oncology (2023) Vol. 41, Iss. 32, pp. 5044-5048
Closed Access | Times Cited: 2
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Andrea Duminuco, Antonella Nardo, Giuseppe A. Palumbo
Hematological Oncology (2024) Vol. 42, Iss. 2
Closed Access
Recent advances in JAK2 inhibition for the treatment of myelofibrosis
Noa Rippel, Marina Kremyanskaya
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1175-1186
Closed Access
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
Maria Stella Pennisi, Sandra Di Gregorio, Elena Tirrò, et al.
Hematology Reports (2023) Vol. 15, Iss. 2, pp. 317-324
Open Access | Times Cited: 1
Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study
Kira‐Lee Koster, Nora-Medea Messerich, Thomas Volken, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4698-4698
Open Access | Times Cited: 1
Page 1

Scroll to top